Genoway: 2025 Financial Results & Strategic Shift to Data Science | Lyon Entreprises

Genoway: 2025 Financial Results & Strategic Shift to Data Science | Lyon Entreprises

January 28, 2026 discoverhiddenusacom Business

The Lyon-based preclinical solutions company, genOway, reported consolidated revenue of €21.0 million in 2025, a slight decrease of 5 percent year-over-year. Despite this dip, the company anticipates accelerated activity beginning in 2026, driven by a reorganization of its commercial structure and an expansion into data science and artificial intelligence.

Second-Half Stabilization Following a Challenging First Half

For the fiscal year ending December 31, 2025, genOway’s annual revenue reached €21.0 million, compared to €22.1 million in 2024. The first half of 2025 saw a 10 percent decline in activity, while the second half generated €11.4 million, remaining stable compared to the same period in 2024.

The company attributes this performance to a generally cautious economic environment, coupled with the ongoing transformation of its commercial organization, which included new hires and structural changes.

Strengthened Strategic Roadmap in 2025

2025 was described as a pivotal year for genOway, marked by the implementation of the ROUTE 50+ strategic plan. This plan included a complete overhaul of the commercial organization and a new marketing initiative designed to increase brand awareness and promote innovation.

The launch of new models in immuno-oncology and immuno-inflammation, alongside strengthened commercial and marketing resources, contributed to the recovery of activity in the second half of the year.

Did You Know? genOway aims to achieve €0.8 million in savings during the 2025 fiscal year, with an additional €1.4 million in savings projected for 2026.

Maintained Investments and Profitability Aligned with Plan

Throughout 2025, genOway continued to invest in commercial activities and research and development, while simultaneously implementing cost-saving and productivity improvement measures. The company aims to maintain an EBITDA margin exceeding 15 percent throughout the ROUTE 50+ plan. The EBITDA margin for the first half of 2025 was 16.9 percent.

A Shift Towards Predictive Data with ROUTE50+DATA

In late 2025, genOway expanded its strategic plan, rebranding it as ROUTE50+DATA, following the acquisition of assets from an international platform specializing in OMICS, data science, and artificial intelligence, originally developed by the BIOASTER institute.

This acquisition, funded by a €7 million private placement in December 2025, is expected to provide genOway with a technological platform integrating expertise, equipment, and facilities by the end of the first quarter of 2026. The company believes this accelerates its timeline by approximately one year.

The new predictive data activity is projected to generate initial revenue in 2026, particularly through pre-competitive consortia with pharmaceutical partners, with a positive contribution to profitability anticipated from 2027.

Expert Insight: The strategic shift towards data science and AI represents a significant evolution for genOway, potentially unlocking new revenue streams and enhancing its competitive position in the preclinical solutions market. Successfully integrating the acquired assets and forging pharmaceutical partnerships will be crucial for realizing these benefits.

Strengthened Growth Objectives for 2026 and Beyond

For 2026, genOway has set a target for organic revenue growth exceeding 10 percent, aiming for revenue of over €23 million. This trajectory relies on the launch of two new catalog model lines in inflammation and safety, currently undergoing validation.

International expansion is another strategic focus, with anticipated growth in the activity of the genOway Shanghai joint venture in China. The company expects a doubling of revenue in 2026 compared to 2025, with a target of between €5 and €10 million in revenue by 2028.

Long-term, genOway reaffirms its goal of reaching €50 million in revenue by 2028, accompanied by an EBITDA margin exceeding 15 percent. These targets are scheduled for review in 2026 to incorporate revenue from the data activity.

Renewed Financial Leadership

genOway announced the appointment of Marie-Laure Warlouzet as Chief Administrative and Financial Officer, following the departure of Benjamin Bruneau. Warlouzet brings 20 years of experience in financial leadership roles within international groups, large companies, and SMEs. Prior to joining genOway, she served as CFO of Iten and previously held leadership positions at Elmy, Sandvik, and Toray.

Frequently Asked Questions

What was genOway’s revenue in 2025?

genOway reported consolidated revenue of €21.0 million in 2025, a 5 percent decrease compared to €22.1 million in 2024.

What is the ROUTE50+DATA plan?

ROUTE50+DATA is genOway’s expanded strategic plan, following the acquisition of assets in OMICS, data science, and artificial intelligence, initially developed by the BIOASTER institute.

What are genOway’s revenue goals for 2026?

genOway aims for organic revenue growth exceeding 10 percent in 2026, targeting revenue of over €23 million.

As genOway navigates its strategic shift towards data-driven solutions, how might evolving partnerships with pharmaceutical companies shape the future of preclinical research?